Although there are yet questions that remain answered regarding their mechanism of action and clinical utility, the compounds discovered by Odolczyk et al (2013) evidently represent a novel family of CFTR correctors for CF drug intervention. This evidence concerns the gene CFTR and cystic fibrosis.